Literature DB >> 2362273

Conformational restriction of angiotensin II: cyclic analogues having high potency.

K L Spear1, M S Brown, E J Reinhard, E G McMahon, G M Olins, M A Palomo, D R Patton.   

Abstract

Cyclic analogues of angiotensin II (AII) were synthesized by connecting the side chains of residues 3 and 5 via a disulfide bridge. Appropriate conformational constraints afforded an analogue, [Hcy3,5]AII, having high contractile activity (pD2 = 8.48 vs 8.81 for AII) and excellent binding affinity (IC50 = 2.1 nM vs 2.2 nM for AII). This type of cyclization was also used to prepare a highly potent AII antagonist, [Sar1,Hcy3,5,Ile8]AII (pA2 = 9.09 vs 9.17 for [Sar1, Ile8]AII; IC50 = 0.9 nM vs 1.9 nM for [Sar1,Ile8]AII). Model building suggests that this ring structure is consistent with a receptor-bound conformation having any of a variety of three-residue turns, including a gamma-turn. In contrast, the receptor-bound conformation of AII does not appear to accommodate a beta-turn or an alpha-helix which includes residues 3-5.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2362273     DOI: 10.1021/jm00169a019

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Structure-Guided Design of Novel, Potent, and Selective Macrocyclic Plasma Kallikrein Inhibitors.

Authors:  Zhe Li; James Partridge; Abel Silva-Garcia; Peter Rademacher; Andreas Betz; Qing Xu; Hing Sham; Yunjin Hu; Yuqing Shan; Bin Liu; Ying Zhang; Haijuan Shi; Qiong Xu; Xubo Ma; Li Zhang
Journal:  ACS Med Chem Lett       Date:  2016-12-06       Impact factor: 4.345

2.  Derivation of a 3D pharmacophore model for the angiotensin-II site one receptor.

Authors:  K Prendergast; K Adams; W J Greenlee; R B Nachbar; A A Patchett; D J Underwood
Journal:  J Comput Aided Mol Des       Date:  1994-10       Impact factor: 3.686

3.  Angiotensin II-derived constrained peptides with antiplasmodial activity and suppressed vasoconstriction.

Authors:  Adriana Farias Silva; Marcelo Der Torossian Torres; Leandro Souza Silva; Flavio Lopes Alves; Ana Acácia de Sá Pinheiro; Antonio Miranda; Margareth Lara Capurro; Cesar de la Fuente-Nunez; Vani Xavier Oliveira
Journal:  Sci Rep       Date:  2017-10-30       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.